Anavex life sciences to participate in the annual needham virtual neuroscience forum

New york, march 09, 2022 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today announced that christopher u. missling, phd, president and chief executive officer of anavex, will participate in the annual needham virtual neuroscience forum in a fireside chat on wednesday, march 16th 2022 at 8:00 am et.
AVXL Ratings Summary
AVXL Quant Ranking